血液学
首页 / 澳门葡京赌博游戏的治疗领域 / 肿瘤学 /血液学
Despite great strides in the treatment and understanding of blood 癌症s in recent years, there remain critical unmet needs for this diverse and complex family of diseases. These significant gaps in treating and caring for patients with blood 癌症 are why 澳门葡京网赌游戏 is committed to help transform the haematologic 癌症 care experience.
澳门葡京赌博游戏努力成为血液学的科学领导者，帮助照顾3.截至2020年，全球有600万人患有血癌*.1
血癌是一个多样而复杂的疾病家族. 有血癌和相关的血液疾病, 骨髓或淋巴结, 包括白血病, 淋巴瘤和骨髓瘤.2 在血液恶性肿瘤中, 澳门葡京赌博游戏的核心研究领域包括急性髓性白血病(AML)。, 骨髓增生异常综合征(MDS), 慢性淋巴细胞性白血病, 弥漫大b细胞淋巴瘤(DLBCL), 套细胞淋巴瘤和多发性骨髓瘤.
Applying our deep understanding of blood 癌症s and leveraging our strength in solid tumour oncology, we are driving the development of novel therapies designed to target underlying drivers of disease across six scientific platforms. 澳门葡京赌博游戏的标志性平台包括抗体药物偶联物, immuno-oncology, DNA损伤反应, 肿瘤驱动因素和耐药性, 细胞治疗和表观遗传学.
通过寻求解决高未满足需求的血癌, our aim is to deliver new medicines and approaches to healthcare services that have a meaningful impact on patients and 照顾者s, 改变血液学癌症护理体验.
勇于承担科学驱动的风险
澳门葡京赌博游戏的做法大胆无畏, 勇于创新，勇于担当, 由科学推动风险. 澳门葡京赌博游戏由科学推动, risk-taking strategy is based on the fundamental principle that we do what is right for patients, 澳门葡京赌博游戏追求卓越的科学.
Our robust development programme includes more than 11 company-sponsored clinical trials across multiple B-cell blood 癌症s, 通过III期临床前开发的研究药物.3 We encourage scientific exploration with a smart risk-taking process that allows us to adapt and evolve, 加快有希望的项目.
The breadth and depth of our pipeline enables us to explore potential synergies between our own molecules and look at combinations with standard of care where the addition of a novel combination partner may help address an unmet medical need.
根据患者的见解，对血液病护理产生有意义的影响
每个人都受到血癌的影响, 他们是否是病人, 照顾者, 家人或朋友, is another reason our researchers work every day to advance the science in haematology. 澳门葡京赌博游戏很自豪能成为血癌社区的一部分并与之合作, 在开发的关键决策点整合患者的见解, to help transform healthcare delivery and create new treatment options for those battling blood 癌症s.
慢性淋巴细胞白血病:一种常见而复杂的血癌
CLL是成人中最常见的白血病类型, 估计有114人,2017年全球新发病例达1万例, and the number of people living with CLL is expected to grow with improved treatment as patients live longer with the disease.4,5,6,7
在慢性淋巴细胞白血病, 癌症ous ce在那 crowd the bone marrow leaving less room for healthy white blood ce在那, 红细胞和血小板. 这会导致感染、贫血和出血.5 当CLL细胞主要出现在淋巴结时, 它们被称为小淋巴细胞淋巴瘤(SLL)细胞.8 大多数CLL患者有多种合并症, 虽然疾病进展和并发症是死亡的主要原因.9
有一些治疗方案可以帮助管理CLL, 然而, 一些病人, 包括那些年龄较大或有其他疾病的人, 现有的治疗方法可能会产生严重的长期或晚期影响.10,11 For many patients with CLL, the disease may return even after successful treatment.12 新的治疗方法旨在满足CLL患者的这些需求.
CLL is characterised by a variety of molecular abnormalities that are responsible for disease development, 进步与转变.13 The presence of certain biomarkers in CLL is increasingly used to inform the best course of treatment.14
随着澳门葡京赌博游戏对CLL理解的进步, we are learning more about the disease’s biomarkers and the valuable role their presence plays in determining a patient’s risk category and in guiding treatment decisions.13,15
套细胞淋巴瘤:一种罕见且易变的癌症
淋巴瘤是淋巴系统的一种血癌. 它是由淋巴细胞(一种白细胞)的快速产生引起的.16 B ce在那 and T ce在那 are the two types of lymphocytes that can develop into lymphomas.17 The two main types of lymphoma are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL).16 MCL is a rare NHL typically resulting when B-lymphocytes mutate into malignant ce在那 within a region of the lymph node known as the mantle zone.18,19
MCL is often diagnosed as a late-stage disease after it has spread to the gastrointestinal tract and bone marrow.18 MCL的临床表现和侵袭性各不相同. 症状可能包括淋巴结肿胀, 发热, 盗汗, 体重减轻和疲劳, though some people have zero to few signs of MCL leading to delayed diagnosis and treatment.17,19
There is no cure for MCL; 然而, 有一些治疗方案可以帮助控制这种疾病, 最近的治疗进展改善了患者的治疗效果. 不幸的是，对许多患者来说，这种疾病在治疗后可能会复发.20 Additional treatment options are needed for people who relapse or do not respond to treatment.
其他主要疾病领域
引用:
1. 世界卫生组织. Worldwide Cancer Fact Sheet 2020 (Incidence, 死亡率 and Prevalence by 癌症 site). http://gco.研究.fr /今天/数据/资料/数量/ 900 -世界-事实表.pdf. 2023年6月访问.
2. 白血病及淋巴瘤学会. 事实和统计数据概述. http://www.在那.org/facts-and-statistics/facts-and-statistics-overview. 2023年6月访问.
3. 澳门葡京网赌游戏. 临床试验，第一季度2023结果更新. 2023年3月出版. 可在:http://www.AstraZeneca.com/content/dam/az/pdf/2023/q1/q1 - 2023 -临床试验结果——附录.pdf. 2023年6月访问.
4. 美国癌症协会. 什么是慢性淋巴细胞白血病? 可在http://www下载.癌症.org/癌症/chronic-lymphocytic-leukemia/about/what-is-cll.html. 2023年6月访问.
5. 国家癌症研究所. 慢性淋巴细胞白血病治疗(PDQ®)-患者版. 可在http://www下载.癌症.gov /类型/白血病/耐心/ cll-treatment-pdq. 2023年6月访问.
6. 全球疾病负担癌症合作. 全球, 区域, 和全国癌症发病率, 死亡率, 逝去的生命岁月, 残疾生活年数, 和29个癌症组的残疾调整生命年, 1990 to 2017. JAMA杂志. 2019;54(12):1749-1768.
7. Jain N，等. Prevalence and Economic Burden of Chronic Lymphocytic 白血病 (CLL) in the Era of Oral Targeted Therapies. 血. 2015;126:871.
8. 国家癌症研究所. NCI字典. 慢性淋巴细胞白血病/ SLL. 可在:http://www.癌症.gov /出版物/字典/ 癌症-terms / def / cll-sll. 2023年6月访问.
9. Strati P，等. Disease Progression and Complications Are the Main Cause of Death in Patients with Chronic Lymphocytic 白血病 (CLL) Independent of Age and Comorbidities at Diagnosis. 血. 2015;126(23):5265.
10. 白血病 & 淋巴瘤的社会. 治疗类型. 可在:http://www.在那.org/treatment/types-of-treatment. 2023年6月访问.
11. 白血病 & 淋巴瘤的社会. 癌症幸存者的长期和晚期影响. 可在:http://www.在那.org/managing-your-癌症/long-term-and-late-effects-for-癌症-survivors. 2023年6月访问.
12. 淋巴瘤研究基金会. 了解慢性淋巴细胞白血病/小淋巴细胞淋巴瘤. 可在:http://lymphoma.org/wp-content/uploads/2020/11/LRF_FACTSHEET_CLL_SLL-1.pdf. 2023年6月访问.
13. Moia R，等. 慢性淋巴细胞白血病的精准医学治疗. 癌症. 2020年3月10日;12(3):642. Doi: 10.3390 / 癌症s12030642.
14. Amaya-Chanaga CI和Rassenti LZ. Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers. 最佳实践治疗临床血液病. 2016年3月,29 (1):79 - 89.
15. Lee J和Want YL. 慢性淋巴细胞白血病的预后和预测性分子生物标志物. J分子诊断. 2020年9月1日;22(9):1114-1125.
16. 淋巴瘤研究基金会. 对淋巴瘤. http://lymphoma.org/aboutlymphoma/. 2023年6月访问.
17. 淋巴瘤研究基金会. 非霍奇金淋巴瘤(NHL). http://lymphoma.org/aboutlymphoma/nhl/. 2023年6月访问.
18. 淋巴瘤研究基金会. 套细胞淋巴瘤. http://lymphoma.org/aboutlymphoma/nhl/mcl/. 2023年6月访问.
19. 国家罕见疾病组织. 套细胞淋巴瘤. http://rarediseases.org/rare-diseases/mantle-cell-lymphoma/. 2023年6月访问.
20. 白血病 & 淋巴瘤的社会. 套细胞淋巴瘤事实. http://www.在那.org/sites/default/files/file_assets/mantlecelllymphoma.pdf. 2023年6月访问.
Veeva ID: Z4-55130
筹备日期:2023年6月